Ionis Pharmaceuticals announces $500M common stock offering

Ionis Pharmaceuticals announced a proposed underwritten public offering of $500M of its common stock. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs, earlier pipeline programs, and research and development activities, as well as for working capital and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Morgan Stanley and Goldman Sachs & Co. are acting as joint book-running managers for the offering.